253 related articles for article (PubMed ID: 34353870)
1. Impact of
Brendle C; Maier C; Bender B; Schittenhelm J; Paulsen F; Renovanz M; Roder C; Castaneda-Vega S; Tabatabai G; Ernemann U; Fougère C
J Nucl Med; 2022 Apr; 63(4):522-527. PubMed ID: 34353870
[TBL] [Abstract][Full Text] [Related]
2. The diagnostic accuracy of detecting malignant transformation of low-grade glioma using O-(2-[18F]fluoroethyl)-l-tyrosine positron emission tomography: a retrospective study.
Bashir A; Brennum J; Broholm H; Law I
J Neurosurg; 2018 Apr; 130(2):451-464. PubMed ID: 29624154
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Value of O-(2-[18F]-Fluoroethyl)-L-Tyrosine-Positron Emission Tomography Imaging for Histopathologic Characteristics and Progression-Free Survival in Patients with Low-Grade Glioma.
Bette S; Gempt J; Delbridge C; Kirschke JS; Schlegel J; Foerster S; Huber T; Pyka T; Zimmer C; Meyer B; Ringel F
World Neurosurg; 2016 May; 89():230-9. PubMed ID: 26855307
[TBL] [Abstract][Full Text] [Related]
4. Hybrid
Smith NJ; Deaton TK; Territo W; Graner B; Gauger A; Snyder SE; Schulte ML; Green MA; Hutchins GD; Veronesi MC
J Nucl Med; 2023 Jul; 64(7):1087-1092. PubMed ID: 37116915
[TBL] [Abstract][Full Text] [Related]
5. Potential for differentiation of glioma recurrence from radionecrosis using integrated
Sogani SK; Jena A; Taneja S; Gambhir A; Mishra AK; D'Souza MM; Verma SM; Hazari PP; Negi P; Jadhav GK
Neurol India; 2017; 65(2):293-301. PubMed ID: 28290392
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of O-(2-18F-fluoroethyl)-L-tyrosine PET and MRI in low-grade glioma.
Floeth FW; Pauleit D; Sabel M; Stoffels G; Reifenberger G; Riemenschneider MJ; Jansen P; Coenen HH; Steiger HJ; Langen KJ
J Nucl Med; 2007 Apr; 48(4):519-27. PubMed ID: 17401087
[TBL] [Abstract][Full Text] [Related]
7. Correlation of Dynamic O-(2-[
Lohmann P; Piroth MD; Sellhaus B; Weis J; Geisler S; Oros-Peusquens AM; Mohlberg H; Amunts K; Shah NJ; Galldiks N; Langen KJ
World Neurosurg; 2018 Nov; 119():e653-e660. PubMed ID: 30077752
[TBL] [Abstract][Full Text] [Related]
8. Serial 18F-FET PET Imaging of Primarily 18F-FET-Negative Glioma: Does It Make Sense?
Unterrainer M; Schweisthal F; Suchorska B; Wenter V; Schmid-Tannwald C; Fendler WP; Schüller U; Bartenstein P; Tonn JC; Albert NL
J Nucl Med; 2016 Aug; 57(8):1177-82. PubMed ID: 27033893
[TBL] [Abstract][Full Text] [Related]
9. Fully automated analysis combining [
Paprottka KJ; Kleiner S; Preibisch C; Kofler F; Schmidt-Graf F; Delbridge C; Bernhardt D; Combs SE; Gempt J; Meyer B; Zimmer C; Menze BH; Yakushev I; Kirschke JS; Wiestler B
Eur J Nucl Med Mol Imaging; 2021 Dec; 48(13):4445-4455. PubMed ID: 34173008
[TBL] [Abstract][Full Text] [Related]
10. Detection of recurrent high-grade glioma using microstructure characteristics of distinct metabolic compartments in a multimodal and integrative 18F-FET PET/fast-DKI approach.
Lohmeier J; Radbruch H; Brenner W; Hamm B; Hansen B; Tietze A; Makowski MR
Eur Radiol; 2024 Apr; 34(4):2487-2499. PubMed ID: 37672058
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic Accuracy of MR Spectroscopic Imaging and
Mauler J; Lohmann P; Maudsley AA; Sheriff S; Hoevels M; Meissner AK; Hamisch C; Brunn A; Deckert M; Filss CP; Stoffels G; Dammers J; Ruge MI; Galldiks N; Mottaghy FM; Langen KJ; Shah NJ
J Nucl Med; 2024 Jan; 65(1):16-21. PubMed ID: 37884332
[TBL] [Abstract][Full Text] [Related]
12. Glioma Recurrence Versus Radiation Necrosis: Single-Session Multiparametric Approach Using Simultaneous O-(2-18F-Fluoroethyl)-L-Tyrosine PET/MRI.
Jena A; Taneja S; Gambhir A; Mishra AK; Dʼsouza MM; Verma SM; Hazari PP; Negi P; Jhadav GK; Sogani SK
Clin Nucl Med; 2016 May; 41(5):e228-36. PubMed ID: 26859208
[TBL] [Abstract][Full Text] [Related]
13. The positive predictive value of O-(2-[18F]fluoroethyl)-L-tyrosine (FET) PET in the diagnosis of a glioma recurrence after multimodal treatment.
Mehrkens JH; Pöpperl G; Rachinger W; Herms J; Seelos K; Tatsch K; Tonn JC; Kreth FW
J Neurooncol; 2008 May; 88(1):27-35. PubMed ID: 18217207
[TBL] [Abstract][Full Text] [Related]
14. The use of dynamic O-(2-18F-fluoroethyl)-l-tyrosine PET in the diagnosis of patients with progressive and recurrent glioma.
Galldiks N; Stoffels G; Filss C; Rapp M; Blau T; Tscherpel C; Ceccon G; Dunkl V; Weinzierl M; Stoffel M; Sabel M; Fink GR; Shah NJ; Langen KJ
Neuro Oncol; 2015 Sep; 17(9):1293-300. PubMed ID: 26008606
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic yield of simultaneous dynamic contrast-enhanced magnetic resonance perfusion measurements and [
Henriksen OM; Hansen AE; Muhic A; Marner L; Madsen K; Møller S; Hasselbalch B; Lundemann MJ; Scheie D; Skjøth-Rasmussen J; Poulsen HS; Larsen VA; Larsson HBW; Law I
Eur J Nucl Med Mol Imaging; 2022 Nov; 49(13):4677-4691. PubMed ID: 35907033
[TBL] [Abstract][Full Text] [Related]
16. 18F-FET PET differentiation of ring-enhancing brain lesions.
Floeth FW; Pauleit D; Sabel M; Reifenberger G; Stoffels G; Stummer W; Rommel F; Hamacher K; Langen KJ
J Nucl Med; 2006 May; 47(5):776-82. PubMed ID: 16644747
[TBL] [Abstract][Full Text] [Related]
17. Radiotherapy target volume definition in newly diagnosed high grade glioma using
Dissaux G; Dissaux B; Kabbaj OE; Gujral DM; Pradier O; Salaün PY; Seizeur R; Bourhis D; Ben Salem D; Querellou S; Schick U
Radiother Oncol; 2020 Sep; 150():164-171. PubMed ID: 32580001
[TBL] [Abstract][Full Text] [Related]
18. Radiotherapy Target Volume Definition in Newly Diagnosed High-Grade Glioma Using 18F-FET PET Imaging and Multiparametric MRI: An Inter Observer Agreement Study.
Dissaux B; Mazouz Fatmi D; Ognard J; Allard B; Keromnes N; Latreche A; Lepeuve A; Schick U; Bourbonne V; Ben Salem D; Dissaux G; Querellou S
Tomography; 2022 Aug; 8(4):2030-2041. PubMed ID: 36006068
[TBL] [Abstract][Full Text] [Related]
19. An interindividual comparison of O-(2-[18F]fluoroethyl)-L-tyrosine (FET)- and L-[methyl-11C]methionine (MET)-PET in patients with brain gliomas and metastases.
Grosu AL; Astner ST; Riedel E; Nieder C; Wiedenmann N; Heinemann F; Schwaiger M; Molls M; Wester HJ; Weber WA
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):1049-58. PubMed ID: 21570201
[TBL] [Abstract][Full Text] [Related]
20. The use of O-(2-18F-fluoroethyl)-L-tyrosine PET for treatment management of bevacizumab and irinotecan in patients with recurrent high-grade glioma: a cost-effectiveness analysis.
Heinzel A; Müller D; Langen KJ; Blaum M; Verburg FA; Mottaghy FM; Galldiks N
J Nucl Med; 2013 Aug; 54(8):1217-22. PubMed ID: 23785172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
